Eton Pharmaceuticals (ETON) CCO receives stock options and RSUs grant

Rhea-AI Filing Summary

Eton Pharmaceuticals Chief Commercial Officer Erdogan-Trinkaus Ipek reported new equity awards. On January 12, 2026, the executive received an employee stock option for 40,655 shares of common stock at an exercise price of $15.47 per share. These options vest in 48 equal monthly installments from the grant date and become fully vested and exercisable on January 12, 2030.

The filing also shows a grant of 25,856 restricted stock units (RSUs), each representing one share of ETON common stock. The RSUs vest in four equal annual installments beginning on January 12, 2027, conditional on continued employment on each vesting date. After these grants, the reporting person beneficially owns 123,878 derivative securities tied to options and 149,734 derivative securities tied to RSUs.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Erdogan-Trinkaus Ipek

(Last) (First) (Middle)

C/O ETON PHARMACEUTICALS, INC.

21925 W. FIELD PARKWAY, SUITE 235

(Street)

DEERPARK IL 60010-7208

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Eton Pharmaceuticals, Inc. [ ETON ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$15.47	01/12/2026		A		40,655		(1)	01/11/2036	Common Stock	40,655	$0	123,878	D
Restricted Stock Units	(2)	01/12/2026		A		25,856		(3)	(3)	Common Stock	25,856	$0	149,734	D

Explanation of Responses:

1. The shares subject to the option shall vest in 48 equal monthly installments from the date of grant until fully vested and exercisable on January 12, 2030.

2. Each restricted stock unit represents a contingent right to receive one share of ETON Common Stock.

3. The restricted stock units vest in four equal annual installments beginning January 12, 2027, contingent upon the reporting person being employed by the issuer on the date(s) of vesting.

Remarks:

The signing person has authorized and designated the named person to file this Form 4 on the reporting person's behalf for indefinite duration.

	/s/ James R. Gruber	01/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did ETON report in this Form 4?

The Form 4 reports that Chief Commercial Officer Erdogan-Trinkaus Ipek received an employee stock option for 40,655 shares and a grant of 25,856 restricted stock units on January 12, 2026.

What are the terms of the stock options granted to the ETON CCO?

The employee stock option covers 40,655 shares of Eton Pharmaceuticals common stock with an exercise price of $15.47 per share and vests in 48 equal monthly installments until fully vested on January 12, 2030.

How do the restricted stock units (RSUs) for ETONs CCO vest?

The 25,856 RSUs vest in four equal annual installments beginning on January 12, 2027, and each RSU represents a contingent right to receive one share of ETON common stock, subject to continued employment on each vesting date.

How many derivative securities does the ETON CCO own after these grants?

After the reported transactions, the CCO beneficially owns 123,878 derivative securities related to options and 149,734 derivative securities related to restricted stock units, all reported as held directly.

Who is the reporting person in this ETON Form 4 filing and what is their role?

The reporting person is Erdogan-Trinkaus Ipek, who serves as Chief Commercial Officer of Eton Pharmaceuticals, Inc., and the filing is made by one reporting person.

Does this ETON Form 4 indicate any sale of shares by the CCO?

No sales are reported; the Form 4 only shows acquisitions of an employee stock option and restricted stock units, each reported with transaction code A for acquisition.